|
|
Volumn 6, Issue 5, 2000, Pages 188-189
|
|
Antiangiogenic therapy: Preclinical premise and promise
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2 METHOXYESTRADIOL;
2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID;
3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE;
ANGIOGENESIS INHIBITOR;
ANGIOSTATIN;
CANCER ANTIBODY;
COMBRETASTATIN;
CYTOTOXIC AGENT;
ENDOSTATIN;
FUMAGILLOL CHLOROACETYLCARBAMATE;
HALOFUGINONE;
MATRIX METALLOPROTEINASE INHIBITOR;
MONOCLONAL ANTIBODY DC101;
N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE;
PACLITAXEL;
PROTEIN TYROSINE KINASE INHIBITOR;
RECEPTOR SUBTYPE;
SQUALAMINE;
UNCLASSIFIED DRUG;
VANDETANIB;
VASCULOTROPIN;
VASCULOTROPIN RECEPTOR;
VINBLASTINE;
ANGIOGENESIS;
ANTINEOPLASTIC ACTIVITY;
BREAST CARCINOMA;
CANCER;
CANCER CHEMOTHERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER RECURRENCE;
CONFERENCE PAPER;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG RESEARCH;
EVIDENCE BASED MEDICINE;
HUMAN;
NEUROBLASTOMA;
NONHUMAN;
TUMOR VASCULARIZATION;
|
|
EID: 0034063407
PISSN: 13574310
EISSN: None
Source Type: Journal
DOI: 10.1016/S1357-4310(00)01672-5 Document Type: Conference Paper |
|
Times cited : (2)
|
|
References (0)
|
